Agency Forms Undergoing Paperwork Reduction Act Review, 52110-52111 [2019-21167]
Download as PDF
<![CDATA[
52110
Federal Register / Vol. 84, No. 190 / Tuesday, October 1, 2019 / Notices
Request for Comments
In accordance with the above-cited
Paperwork Reduction Act legislation,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) Whether the
proposed collection of information is
necessary for the proper performance of
AHRQ health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Dated: September 25, 2019.
Virginia L. Mackay-Smith,
Associate Director.
[FR Doc. 2019–21239 Filed 9–30–19; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–19–19AXA]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Annual
Reporting of the Rape Prevention and
Education (RPE) Program: CE19–1902
Cooperative Agreement’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on June 5,
2019 to obtain comments from the
public and affected agencies. One public
comment public comment was received.
This notice serves to allow an additional
30 days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
Annual Reporting of the Rape
Prevention and Education (RPE)
Program: CE19–1902 Cooperative
Agreement—New—National Center for
Injury Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
CDC’s Division of Violence
Prevention (DVP) provides national
leadership in prevention of sexual
violence (SV) perpetration and
victimization before it begins (i.e.,
primary prevention). DVP administers
the RPE Program, which provides
funding to health departments in all 50
states, the District of Columbia (DC),
Puerto Rico, Guam, the U.S. Virgin
Islands, and the Commonwealth of
Northern Mariana Islands. The CDC
seeks OMB approval for three years to
collect information related to
implementation and outcomes annually
from recipients funded under the Rape
Prevention and Education (RPE): Using
The Best Available Evidence for Sexual
Violence Prevention cooperative
agreement.
RPE Program recipients or designated
delegates will submit data annually into
the online data system, DVP Partners
Portal. Recipients will monitor and
report progress on their goals,
objectives, and activities, as well as
relevant information on the
implementation of their prevention
strategies, outcomes, evaluation, and
state action plan.
Information to be collected will
provide crucial data for program
performance monitoring. Information
collected will allow CDC to help ensure
consistency in documenting, enhancing
accountability of the use of federal
funds, providing timely program reports
and responses to information requests,
such as Congressional requests
mandated by the authorizing legislation,
improve real-time communications
between CDC and RPE recipients, and
strengthening CDC’s capacity to provide
responsive data-driven technical
assistance and to monitor and evaluate
recipients’ progress and performance.
Submission of the Annual Progress
Report is required for cooperative
agreement grantees. The total estimated
annualized burden hours are 440. There
is no cost to respondents other than
their time.
jbell on DSK3GLQ082PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
RPE-funded Health Departments (State, DC,
and Territories) and their Designated Delegates.
Annual Reporting—Initial Population .............
Annual Reporting—Subsequent Reporting ....
VerDate Sep<11>2014
19:41 Sep 30, 2019
Jkt 250001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
E:\FR\FM\01OCN1.SGM
Number of
responses per
respondent
55
55
01OCN1
1
2
Average
burden per
response
(in hours)
4
2
Federal Register / Vol. 84, No. 190 / Tuesday, October 1, 2019 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–21167 Filed 9–30–19; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–3767]
Immunology Devices Panel of the
Medical Devices Advisory Committee;
Notice of Meeting; Establishment of a
Public Docket; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Electronic Submissions
Notice; establishment of a
public docket; request for comments.
jbell on DSK3GLQ082PROD with NOTICES
ACTION:
SUMMARY: The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Immunology Devices
Panel of the Medical Devices Advisory
Committee. The general function of the
committee is to provide advice and
recommendations to FDA on scientific
issues. The meeting will be open to the
public. FDA is establishing a docket for
public comment on this document.
DATES: The meeting will be held on
November 13 and 14, 2019, from 8 a.m.
to 6 p.m.
ADDRESSES: Doubletree by Hilton DC
North/Gaithersburg, Grand Ballroom,
620 Perry Pkwy., Gaithersburg, MD
20877. The hotel’s telephone number is
301–977–8900. The hotel’s website is at:
https://doubletree3.hilton.com/en/
hotels/maryland/doubletree-by-hiltonwashington-dc-north-gaithersburgGAIGWDT/. Answers to
commonly asked questions including
information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm408555.htm.
FDA is establishing a docket for
public comments on this meeting. The
docket number is FDA–2019–N–3767.
The docket will close on December 16,
2019. Submit either electronic or
written comments on this public
meeting to the docket by December 16,
VerDate Sep<11>2014
20:09 Sep 30, 2019
Jkt 250001
2019. Please note that late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before December 16, 2019. The
https://www.regulations.gov electronic
filing system will accept comments
until 11:59 p.m. Eastern Time at the end
of December 16, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submission) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Comments received on or before
October 28, 2019, will be provided to
the Committee. Comments received after
that date will be taken into
consideration by FDA. You may submit
comments as follows:
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submission’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
52111
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2019–N–3767 for ‘‘Immunology Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ FDA
will review this copy, including the
claimed confidential information, in its
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 84, Number 190 (Tuesday, October 1, 2019)]
[Notices]
[Pages 52110-52111]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21167]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-19-19AXA]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Annual Reporting of the Rape Prevention and
Education (RPE) Program: CE19-1902 Cooperative Agreement'' to the
Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on June 5, 2019 to obtain comments
from the public and affected agencies. One public comment public
comment was received. This notice serves to allow an additional 30 days
for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to [email protected]. Direct written comments
and/or suggestions regarding the items contained in this notice to the
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide
written comments within 30 days of notice publication.
Proposed Project
Annual Reporting of the Rape Prevention and Education (RPE)
Program: CE19-1902 Cooperative Agreement--New--National Center for
Injury Prevention and Control (NCIPC), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
CDC's Division of Violence Prevention (DVP) provides national
leadership in prevention of sexual violence (SV) perpetration and
victimization before it begins (i.e., primary prevention). DVP
administers the RPE Program, which provides funding to health
departments in all 50 states, the District of Columbia (DC), Puerto
Rico, Guam, the U.S. Virgin Islands, and the Commonwealth of Northern
Mariana Islands. The CDC seeks OMB approval for three years to collect
information related to implementation and outcomes annually from
recipients funded under the Rape Prevention and Education (RPE): Using
The Best Available Evidence for Sexual Violence Prevention cooperative
agreement.
RPE Program recipients or designated delegates will submit data
annually into the online data system, DVP Partners Portal. Recipients
will monitor and report progress on their goals, objectives, and
activities, as well as relevant information on the implementation of
their prevention strategies, outcomes, evaluation, and state action
plan.
Information to be collected will provide crucial data for program
performance monitoring. Information collected will allow CDC to help
ensure consistency in documenting, enhancing accountability of the use
of federal funds, providing timely program reports and responses to
information requests, such as Congressional requests mandated by the
authorizing legislation, improve real-time communications between CDC
and RPE recipients, and strengthening CDC's capacity to provide
responsive data-driven technical assistance and to monitor and evaluate
recipients' progress and performance.
Submission of the Annual Progress Report is required for
cooperative agreement grantees. The total estimated annualized burden
hours are 440. There is no cost to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
RPE-funded Health Departments (State, Annual Reporting-- 55 1 4
DC, and Territories) and their Initial Population. 55 2 2
Designated Delegates. Annual Reporting--
Subsequent Reporting.
----------------------------------------------------------------------------------------------------------------
[[Page 52111]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2019-21167 Filed 9-30-19; 8:45 am]
BILLING CODE 4163-19-P
